Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I)

Key facts

Sponsor

Kiminori Kimura, MD

Principal Investigator

Kiminori Kimura, MD

Tokyo Metropolitan Komagome Hospital

Intervention

OP-724(drug)

Enrollment

7 target

Eligibility

20-74 years · All sexes

Timeline

2019 – 2022

Study locations (2)

• Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Tokyo, Japan
• Kyushu University Hospital, Fukuoka, Japan

Collaborators

Ohara Pharmaceutical Co., Ltd. · Japan Agency for Medical Research and Development

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07449793
  Biochemical Response and Clinical Outcomes in Patients With PBC
  RenJi Hospital
• RECRUITINGPHASE3NCT07296458
  FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
  Xijing Hospital of Digestive Diseases
• RECRUITINGPHASE3NCT07282353
  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
  Cascade Pharmaceuticals, Inc
• RECRUITINGNCT07205874
  Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)
  Hospital Universitario La Paz
• ACTIVE NOT RECRUITINGNCT07049887
  A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
  Ipsen
• RECRUITINGNCT07149675
  PBC Long-term Outcomes Study
  Beijing Friendship Hospital
• RECRUITINGEARLY PHASE1NCT07104201
  Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)
  Xijing Hospital of Digestive Diseases
• RECRUITINGNANCT06861465
  EMPower Mechanisms
  University of Alberta

See all trials for Primary biliary cholangitis →